CRISPR Therapeutics has named Tony Coles to its board of directors. Coles is Chairman and CEO of Yumanity Therapeutics. Prior to that, he was Chariman and CEO of Onyx Pharmaceuticals.
Coles has an MD from Duke University , a master's in public health from Harvard University, and an undergraduate degree from Johns Hopkins University. He completed his medical training in cardiology and internal medicine training at Massachusetts General Hospital and was a Research Fellow at Harvard Medical School.
Coles also serves on the board of directors at McKesson and the board of trustees for Johns Hopkins and Johns Hopkins Medicine.